Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
IPO Year: 2015
Exchange: NYSE
Website: invitae.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/5/2023 | Underweight | JP Morgan | |
| 5/15/2023 | Mkt Perform → Underperform | Raymond James | |
| 1/31/2023 | $2.00 | Neutral → Sell | Goldman |
| 8/25/2022 | $1.00 | Underperform | Credit Suisse |
| 8/10/2022 | Neutral → Underweight | JP Morgan | |
| 7/26/2022 | $8.00 → $2.50 | Outperform → Market Perform | Cowen |
| 7/21/2022 | Outperform → Mkt Perform | Raymond James | |
| 7/20/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 7/19/2022 | Buy → Hold | The Benchmark Company | |
| 7/19/2022 | Outperform → Mkt Perform | SVB Leerink |